Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer’s disease

Memory loss characterizes several neurodegenerative disorders, including Alzheimer’s disease (AD). Inhibition of type 4 phosphodiesterase (PDE4) and elevation of cyclic adenosine monophosphate (cAMP) has emerged as a promising therapeutic approach to treat cognitive deficits. However, PDE4 exists in...

Descripción completa

Detalles Bibliográficos
Autores principales: Ricciarelli, Roberta, Brullo, Chiara, Prickaerts, Jos, Arancio, Ottavio, Villa, Carla, Rebosio, Claudia, Calcagno, Elisa, Balbi, Matilde, van Hagen, Britt T. J., Argyrousi, Elentina K., Zhang, Hong, Pronzato, Maria Adelaide, Bruno, Olga, Fedele, Ernesto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5389348/
https://www.ncbi.nlm.nih.gov/pubmed/28402318
http://dx.doi.org/10.1038/srep46320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5389348/
https://www.ncbi.nlm.nih.gov/pubmed/28402318
http://dx.doi.org/10.1038/srep46320

Ejemplares similares